Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA independent appeals board would be created under PhRMA reform legislation.

This article was originally published in The Tan Sheet

Executive Summary

FDA INDEPENDENT APPEALS BOARD WOULD BE CREATED under draft legislative language being circulated by the Pharmaceutical & Research Manufacturers of America. The PhRMA proposal suggests that the HHS secretary would be directed to establish standing panels of non-government experts "for the purpose of hearing appeals by individuals who have exhausted their informal appeals within FDA and wish to contest the action or failure to act by FDA in a particular matter. The secretary shall establish an appeal procedure that assures immediate access to such a panel and prompt conclusions and recommendations by the panel."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083982

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel